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Abstract A post-Ugi gold-catalyzed regioselective intramolecular car-
bocyclization strategy is reported. A better cationic gold system, com-
pared to our previous report, has been optimized and utilized. The
method presented exhibits excellent functional group compatibility in-
cluding bulky substitutions on alkynes and allows the direct access to
indoloazepinones and indoloazocinones in good to excellent yields.
Key words post-Ugi, gold, indoloazepinone, indoloazocinone, carbo-
cyclization
Synthetic molecules based on natural products play a
major role in the discovery of new therapeutic agents for
treating diseases.2 In this context, the indoloazepinones
skeleton is the core of important natural products such as
the indole alkaloids tronocarpine (I),3 the paullones II,4 and
the malassezindoles III5 (Figure 1). Furthermore, some aze-
pinoindoles possess anticancer activity4b,6 and are found to
be active against central nervous system diseases.7 Owing
to their medicinal value, the development of novel and effi-
cient methods for constructing this heteroarene ring has re-
ceived continuous interest in recent years.8,9 On the other
hand, gold-catalyzed hetereoannulations and carbocycliza-
tions are of contemporary importance due to the selective
and efficient activation of alkynes towards a wide range of
nucleophiles.10
Recently, we reported a concise route to azocino[5,4-
b]indol-4-one via a sequential Ugi gold-catalyzed intramo-
lecular hydroarylation.11 In continuation of this work and as
a result of our interest in transition-metal catalysis12 and
multicomponent reactions13 for the synthesis of diversely
substituted heterocycles, we elaborated a post-Ugi gold-
catalyzed regioselective carbocyclization approach for the
synthesis of indoloazepinones. Moreover, this protocol al-
lows the synthesis of indoloazocinones bearing sterically
hindered substituents on the alkyne, which was not possi-
ble to achieve using our previously reported protocol.11
Ugi four-component reaction (Ugi-4CR)14 of indolemeth-
ylamine 1a, benzaldehyde (2a), but-2-ynoic acid (3a), and
1,1,3,3-tetramethylbutyl isocyanide (4a) in methanol at
room temperature furnishes the corresponding Ugi adduct
5a in 95% yield. This was further used for investigating the
intramolecular carbocyclization (Table 1).
The application of 5 mol% of Au(PPh3)OTf in CDCl3 at
room temperature for 24 hours, resulted in 61% of indoloaze-
pinone 6a, as measured by 1H NMR spectroscopy (Table 1,
entry 1). No amelioration was observed using Au(PPh3)BF4,
AuSbF6, and Au(JohnPhos)SbF6 as catalyst while the use of
Yb(OTf)3 resulted in only traces of the product (entries 2–
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l.5). Interestingly, the application of Au(PPh3)SbF6 substan-
tially enhanced the yield of 6a to 86% (entry 6). Among the
solvents screened, CDCl3 was found to be the solvent of
choice (entries 7 and 8). Reaction with Au(PPh3)SbF6 at
50 °C sped up the reaction and increased the yield to 90%
(entry 9). A decrease of the catalyst loading to 2 mol% re-
sulted in a lower yield even after a prolonged reaction time
(entry 10).
Having optimized the conditions for the intramolecular
carbocyclization (Table 1, entry 9), the scope and limita-
tions of the protocol were explored. A diversely substituted
set of Ugi adducts was synthesized and subjected to the re-
action conditions.
The endo-dig cyclization proceeds smoothly giving the
indoloazepinones in good to excellent yields (Table 2). The
reaction is feasible with Ugi adducts derived from aliphatic
as well as aromatic aldehydes (Table 2, entries 1–6). Inter-
estingly, bulky substituents on the alkyne like ethyl, isopro-
pyl, and aryl are well tolerated (entries 7–10). However, the
Ugi adduct 5k containing a tert-butyl substituent, failed to
give the desired cyclized product (entry 11). As expected,
the terminal alkyne 5l gave the 6-exo-dig product 6l, due to
the involvement of a gold carbene intermediate (entry
12).11,15
Inspired by the observation that Ugi adduct with bulky
substituent like phenyl can also undergo endo-dig carbocy-
clization at high temperature, we were keen to investigate
this modified protocol on previously reported but unsuc-
cessful intramolecular hydroarylation for the synthesis of
indoloazocinones.11,16 To our great satisfaction, the method
works efficiently leading to indoloazocinones in good yields
(Table 3). A comparative study of the new reaction condi-
tions with the previously reported Au(PPh3)OTf-catalyzed
hydroarylation was performed. In most cases, the current
protocol proved to be superior delivering the desired indo-
loazocinones with improved yields.11 Nevertheless, the tert-
butyl appears to be too bulky to give the cyclized product
(Table 3, entry 7).
Based on our observations and literature reports15,17 a
plausible mechanism is depicted in Scheme 2. The counter-
ion SbF6– is believed to be completely dissociated from gold
in solution, thus making it more cationic as compared to
OTf–. Coordination of this cationic gold with the alkyne in 5
Table 1  Optimization of the Intramolecular Carbocylizationa
Entry Catalyst Solvent Temp (°C) Time (h) Yield (%)b
 1 Au(PPh3)OTf CDCl3 r.t. 24 61
 2 Au(PPh3)BF4 CDCl3 r.t. 24 38
 3 AuSbF6 CDCl3 r.t. 24 23
 4 Yb(OTf)3 CDCl3 r.t. 24 traces
 5 Au(L)SbF6c CDCl3 r.t. 24 81
 6 Au(PPh3)SbF6 CDCl3 r.t. 24 86
 7 Au(PPh3)SbF6 CD3CN r.t. 24 59
 8 Au(PPh3)SbF6 THF-d8 r.t. 24 48
 9 Au(PPh3)SbF6 CDCl3 50  4 90 (88)d
10 Au(PPh3)SbF6 CDCl3 50 24 84e
a All reactions were run on a 0.1 mmol scale of 5a using 5 mol% of catalyst; TMB = 1,1,3,3-tetramethylbutyl.
b Yields were determined on the basis of 1H NMR analysis using 3,4,5-trimethoxybenzaldehyde as an internal standard.
c L = 2-(Di-tert-butylphosphino)biphenyl (JohnPhos).
d Isolated yield.
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l.generates intermediate A. In the case of an internal alkyne,
the nucleophilic attack of the 3-position of the indole on
the activated alkyne occurs in an endo-dig fashion generat-
ing intermediate B. This is followed by a 1,2-shift to furnish
intermediate C, which upon deprotonation and protodeau-
ration results in the formation of indoloazepinone 6. In the
case of a terminal alkyne the nucleophilic attack of the 3-
position of the indole occurs in an exo-dig fashion generat-
ing intermediate B′. After 1,2-shift, deprotonation and pro-
todeauration, indolopyridinone 6i is formed.
In summary, we have elaborated an improved cationic
gold-catalyzed post-Ugi intramolecular carbocyclization
protocol for the synthesis of indoloazepinones and indo-
loazocinones. Contrary to our previous work, the new
methodology works equally well with bulky substituents
delivering the compounds in good yields. However, condi-
tions are still not able to tolerate the tert-butyl group, and
attempts to further improve the protocol are in progress.
Table 2  Scope and Limitations of the Intramolecular Carbocyclizationa
Entry Ugi adduct 5 Cyclized product 6
1
5a (95%) 6a (88%)
2
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5e (47%) 6e (74%)
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5h (83%) 6h (60%)
9
5i (90%) 6i (82%)
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All the starting materials, reagents, and catalysts were purchased
from Aldrich or Acros and used as such. For TLC, analytical TLC plates
(Alugram SIL G/UV254 and 70–230 mesh silica gel (E. Merck) were
used. Column chromatography was performed using silica gel (Merck,
60–120 mesh size). Anhydrous solvents were purchased from Acros
Organics and stored over molecular sieves. The chromatographic sol-
vents used for isolation/purification of compounds were distilled pri-
or to use. The chromatographic solvents are mentioned as vol-
ume:volume ratios. Reactions were typically run in oven-dried
screw-cap vial under an inert atmosphere.
1H (300 MHz) and 13C (75.5 MHz) NMR spectra were recorded on a
400 MHz and 300 MHz instruments using CDCl3 and DMSO-d6 as a
solvent. The 1H and 13C chemical shifts are reported in parts per mil-
lion relative to TMS using the residual solvent signal as the internal
reference. Standard abbreviations were used to designate chemical
shift multiplicities. 13C NMR spectra are proton decoupled. Melting
points were determined on a digital Barnsted Electrothermal 9200
apparatus and are uncorrected. Mass spectra were recorded by using
a Kratos MS50TC and a Kratos Mach III system. The ion source tem-
perature was 150–250 °C, as required. High-resolution EI-mass spec-
tra were performed with a resolution of 10 000. The low-resolution
spectra were obtained with a HP5989A MS instrument. The low-reso-
lution ESI-MS were obtained with a Thermo Scientific instrument.
Ugi Products 5a–s and 8a–g; General Procedure
To a solution of substituted amine 1 or 7a,b (1 mmol, 1 equiv) in
MeOH (5 mL) were added successively Na2SO4 (0.3 g), aldehyde 2a–g
(1.2 equiv), alkynoic acid 3a–h (1.2 equiv), and isonitrile 4a–d (1.2
equiv) in a 25 mL round-bottomed flask equipped with a magnetic
stir bar. The reaction mixture was stirred at r.t. for 24 h. After comple-
tion of the reaction, the mixture was diluted with EtOAc (100 mL) and
the organic layer was washed with H2O (50 mL) and brine (50 mL),
dried (MgSO4), and evaporated under reduced pressure. The residue
was subjected to silica gel column chromatography (30–50% EtOAc in
heptane) to afford the respective desired products 5a–l or 8a–g as
solids.
10
5j (80%) 6j (93%)b
11
5k (80%) 6k (0%)
b,c
12
5l (71%) 6l (31%)
a Conditions for the Ugi-4CR: indolemethylamine 1 (1 mmol), aldehyde 2 (1.2 equiv), alkynoic acid 3 (1.2 equiv), and isonitrile 4 (1.2 equiv) in MeOH at r.t. for 24 
h; conditions for the intramolecular carbocyclization: Ugi adduct 5 (0.2 mmol), Au(PPh3)Cl (5 mol%), and AgSbF6 (5 mol%) in CHCl3 (2 mL) at 50 °C for 3–6 h.
b The reaction was performed at 80 °C.
c An unidentified mixture of products were obtained.
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l.Table 3  Expanding the Scope of the Intramolecular Carbocyclization to Indoloazocinones and Comparison with the Previous Protocol
Entry Ugi adduct 8 Yield (%)a Product 9 Yield (%)b Yield (%) 
(previous report)c
1 8a 75 9a 80d  0
2 8b 91 9b 94 80
3 8c 48 9c 97 65
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Ugi products appear as a mixture of two rotamers in their 1H and 13C
NMR spectra and hence the NMR spectra are not very characteristic.




Yield: 447 mg (95%); off-white solid; mp 56–58 °C.
1H NMR (300 MHz, CDCl3): δ = 7.74–7.60 (m, 1 H), 7.48–7.33 (m, 2.6
H), 7.32–7.18 (m, 4.5 H), 7.17–7.03 (m, 1.5 H), 6.91 (s, 0.5 H), 6.03 (s,
0.5 H), 5.61 (s, 0.5H), 5.28 (s, 0.5 H), 5.12 (d, J = 15.81 Hz, 0.5 H), 4.85
(d, J = 15.84 Hz, 0.5 H), 4.72 (d, J = 14.85 Hz, 0.5 H), 4.27 (d, J = 14.88
Hz, 0.5 H), 3.78–3.64 (m, 3 H), 2.04–1.91 (m, 3 H), 1.76–1.64 (m, 0.5
H), 1.33 (d, J = 14.88 Hz, 0.5 H), 1.24 (s, 1.5 H), 1.07 (s, 1.5 H), 0.97 (s,
1.5 H), 0.89–0.65 (m, 10 H), 0.50 (s, 1.5 H).
13C NMR (75 MHz, CDCl3): δ = 167.3, 167.2, 156.0, 155.0, 137.1, 136.7,
135.1, 134.7, 129.8, 129.7, 129.2, 128.8, 128.6, 128.3, 128.2, 127.9,
127.0, 126.8, 122.3, 122.0, 120.0, 119.6, 118.9, 110.4, 109.6, 109.5,
109.4, 91.9, 90.5, 74.0, 73.5, 67.0, 64.1, 55.0, 51.7, 50.4, 45.0, 37.5,
32.7, 31.3, 31.1 (3), 28.4, 28.3, 28.0, 27.6, 4.1 (2).
HRMS: m/z calcd for C30H37N3O2: 471.2886; found: 471.2876.
2-(5,6-Dimethyl-3-oxoazepino[4,3-b]indol-2(1H,3H,6H)-yl)-2-phe-
nyl-N-(2,4,4-trimethylpentan-2-yl)acetamide (6a); Typical Proce-
dure
In a 10 mL screw cap vial charged with the Ugi adduct 5a (0.2 mmol,
94 mg) was added AuPPh3Cl (5 mol%, 5 mg), AgSbF6 (5 mol%, 3.5 mg),
and CHCl3 (2 mL). The reaction vial was sealed and subsequently heat-
ed at 50 °C for 3–6 h. After completion of the reaction (confirmed by
TLC analysis, eluent: 30% Et2O in CH2Cl2), the residue was subjected to
silica gel column chromatography (20–40% Et2O in CH2Cl2) to afford
indoloazepinone 6a; yield: 82 mg (86%); off-white solid; mp 98–
100 °C.
1H NMR (300 MHz, DMSO-d6): δ = 7.58 (br s, 1 H), 7.40 (d, J = 8.28 Hz,
1 H), 7.34–7.23 (m, 3 H), 7.22–7.03 (m, 4 H), 6.90–6.76 (m, 1 H), 6.33
(s, 1 H), 6.05 (s, 1 H), 4.52–4.05 (m, 2 H), 3.82 (s, 3 H), 2.39 (s, 3 H),
1.44–1.11 (m, 8 H), 0.79 (s, 9 H).
13C NMR (75 MHz, CDCl3): δ = 168.0, 167.6, 138.8, 138.1, 135.7, 135.5,
129.3, 128.7, 128.0, 125.7, 124.1, 123.3, 120.1, 119.4, 116.0, 109.3,
62.1, 55.5, 51.9, 38.7, 32.5, 31.3, 28.6, 28.1, 23.2.
5 8e 76 9e 84d NA
6 8f 86 9f 78d 81
7 8g 84 9g  0d  0
a Conditions for the Ugi-4CR: tryptamine 7 (1 mmol), aldehyde 2 (1.1 equiv), alkynoic acid 3 (1.1 equiv), and isonitrile 4 (1.1 equiv) in MeOH at r.t. for 24 h.
b Conditions for the intramolecular carbocyclization: Ugi adduct 8 (0.2 mmol), Au(PPh3)Cl (5 mol%), and AgSbF6 (5 mol%) in CHCl3 (2 mL) at 50 °C for 3–5 h.
c Taken from ref. 10: Au(PPh3)OTf (5 mol%), CHCl3, r.t. 12–24h. NA: Not available.
d The reaction was performed at 80 °C.
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l.HRMS: m/z calcd for C30H37N3O2: 471.2886; found: 471.2863.
N-tert-Butyl-2-(5,6-dimethyl-3-oxoazepino[4,3-b]indol-
2(1H,3H,6H)-yl)-2-phenylacetamide (6b)
Compound 6b was synthesized following the general procedure using
5b (0.2 mmol, 83 mg); yield: 66 mg (80%); off-white solid; mp 143–
145 °C.
1H NMR (300 MHz, DMSO-d6): δ = 7.77 (br s, 1 H), 7.39 (d, J = 8.07 Hz,
1 H), 7.22–7.05 (m, 7 H), 6.89–6.74 (m, 1 H), 6.33 (s, 1 H), 6.01 (s, 1 H),
4.41–4.10 (m, 2 H), 3.83 (s, 3 H), 2.39 (s, 3 H), 1.22 (s, 9 H).
13C NMR (75 MHz, DMSO-d6): δ = 166.3, 138.0, 137.4, 136.6, 135.1,
128.6, 128.4, 127.4, 125.6, 123.3, 122.5, 119.0, 118.5, 115.2, 109.6,
60.5, 50.2, 38.5, 32.1, 28.2, 22.5.
HRMS: m/z calcd for C26H29N3O2: 415.226; found: 415.2262.
N-tert-Butyl-2-(5,6-dimethyl-3-oxoazepino[4,3-b]indol-
2(1H,3H,6H)-yl)pentanamide (6c)
Compound 6c was synthesized following the general procedure using
5c (0.2 mmol, 76 mg); yield: 46 mg (61%); pale yellow solid; mp 117–
119 °C.
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l.1H NMR (300 MHz, CDCl3): δ = 7.68 (d, J = 7.89 Hz, 1 H), 7.35–7.26 (m,
2 H), 7.18 (t, J = 6.8 Hz, 1 H), 6.42 (s, 1 H), 6.01–5.73 (br s, 1 H), 4.82 (d,
J = 7.01 Hz, 1 H), 4.65–4.37 (m, 1 H), 4.34–4.12 (m, 1 H), 3.84 (s, 3 H),
2.41 (s, 3 H), 2.13–1.92 (m, 1 H), 1.76–1.59 (m, 1 H), 1.29–0.89 (m, 11
H), 0.80–0.64 (m, 3 H).
13C NMR (75 MHz, CDCl3): δ = 169.7, 167.8, 139.0, 138.0, 135.9, 125.6,
124.0, 123.4, 120.3, 119.4, 116.1, 109.5, 57.3, 51.0, 37.3, 32.4, 30.2,
28.3, 23.2, 19.2, 13.6.
HRMS: m/z calcd for C23H31N3O2: 381.2416; found: 381.2402.
N-tert-Butyl-2-(5,6-dimethyl-3-oxoazepino[4,3-b]indol-
2(1H,3H,6H)-yl)-3-methylbutanamide (6d)
Compound 6d was synthesized following the general procedure using
5d (0.2 mmol, 76 mg); yield: 60 mg (79%); white solid; mp 182–
184 °C.
1H NMR (300 MHz, DMSO-d6): δ = 7.69 (d, J = 7.73 Hz, 1 H), 7.56 (br s,
1 H), 7.48 (d, J = 8.22 Hz, 1 H), 7.20 (t, J = 7.49 Hz, 1 H), 7.09 (t, J = 7.49
Hz, 1 H), 6.32 (s, 1 H), 4.46 (d, J = 10.87 Hz, 1 H), 3.86 (s, 3 H), 2.39 (s, 3
H), 2.31–2.13 (m, 1 H), 1.12 (s, 9 H), 0.85 (d, J = 6.35 Hz, 3 H), 0.62–
0.10 (m, 3 H).
13C NMR (75 MHz, CDCl3): δ = 168.9, 167.9, 138.9, 137.9, 135.7, 125.5,
124.5, 123.2, 120.2, 119.8, 116.2, 109.2, 63.9, 51.1, 37.3, 32.4, 28.3,
26.7, 23.1, 19.4, 18.6.
HRMS: m/z calcd for C23H31N3O2: 381.2416; found: 381.2415.
N-Cyclohexyl-2-(5,6-dimethyl-3-oxoazepino[4,3-b]indol-
2(1H,3H,6H)-yl)-2-(4-methoxyphenyl)acetamide (6e)
Compound 6e was synthesized following the general procedure using
5e (0.2 mmol, 94 mg); yield: 70 mg (74%); off-white solid; mp 120–
122 °C.
1H NMR (300 MHz, DMSO-d6): δ = 7.99 (br s, 1 H), 7.40 (d, J = 7.92 Hz,
1 H), 7.19–7.00 (m, 3 H), 6.95–9.76 (m, 4 H), 6.31 (s, 1 H), 5.95 (s, 1 H),
4.37–4.12 (m, 1 H), 3.82 (s, 3 H), 3.78–3.66 (m, 4 H), 3.62–3.45 (m, 1
H), 2.38 (s, 3 H), 1.76–1.48 (m, 6 H), 1.20–0.97 (m, 4 H).
13C NMR (75 MHz, CDCl3): δ = 168.5, 167.6, 159.4, 138.7, 138.1, 135.6,
130.5, 127.3, 125.8, 124.0, 123.3, 119.4, 116.1, 114.3, 114.2, 109.2,
55.3, 48.2, 38.5, 32.8, 32.4, 32.3, 25.4, 24.7(2), 24.5, 23.1.
HRMS: m/z calcd for C29H33N3O3: 471.2522; found: 471.2503.
N-Butyl-2-cyclohexyl-2-(5,6-dimethyl-3-oxoazepino[4,3-b]indol-
2(1H,3H,6H)-yl)acetamide (6f)
Compound 6f was synthesized following the general procedure using
5f (0.2 mmol, 84 mg); yield: 62 mg (74%); pale yellow solid; mp 76–
78 °C.
1H NMR (300 MHz, DMSO-d6): δ = 8.01 (br s, 1 H), 7.69 (d, J = 7.14 Hz,
1 H), 7.49 (d, J = 8.10 Hz, 1 H), 7.21 (t, J = 7.49 Hz, 1 H), 7.11 (t, J = 7.49
Hz, 1 H), 6.31 (s, 1 H), 4.53 (d, J = 11.10 Hz, 1 H), 3.85 (s, 3 H), 3.23–
2.64 (m, 2 H), 2.38 (s, 3 H), 2.07–1.85 (m, 1 H), 1.69–1.36 (m, 4 H),
1.28–0.63 (m, 15 H).
13C NMR (75 MHz, DMSO-d6): δ = 166.2, 138.3, 137.6, 134.4, 126.1,
123.8, 122.6, 119.5, 115.4, 109.9, 60.4, 37.9, 36.3, 32.1, 30.7, 29.1,
28.8, 25.7, 25.1, 24.7, 22.4, 19.3, 13.5.
HRMS: m/z calcd for C26H35N3O2: 421.2729; found: 421.2717.
N-Cyclohexyl-2-(5-ethyl-6-methyl-3-oxoazepino[4,3-b]indol-
2(1H,3H,6H)-yl)-2-(4-methoxyphenyl)acetamide (6g)
Compound 6g was synthesized following the general procedure using
5g (0.2 mmol, 97 mg); yield: 75 mg (77%); light yellow solid; mp 118–
119 °C.
1H NMR (300 MHz, CDCl3): δ = 7.98 (br s, 1 H), 7.40 (d, J = 8.28 Hz, 1
H), 7.24–6.89 (m, 4 H), 6.88–6.63 (m, 3 H), 6.33 (s, 1 H), 5.96 (s, 1 H),
4.47–4.03 (m, 1 H), 3.80 (s, 3 H), 3.75–3.44 (m, 5 H), 2.88–2.61 (m, 2
H), 1.83–1.44 (m, 5 H), 1.33–1.12 (m, 3 H), 1.11–0.94 (m, 5 H).
13C NMR (75 MHz, CDCl3): δ = 167.8, 159.4, 141.8, 138.8, 137.4, 130.6,
127.2, 124.3, 124.1, 123.1, 119.3, 116.6, 114.2, 109.2, 61.6, 55.3, 48.2,
38.5, 32.3, 30.9, 29.2, 25.4, 24.5, 22.3, 14.0, 13.3.
HRMS: m/z calcd for C30H35N3O3: 485.2678; found: 485.2649.
N-tert-Butyl-2-(5-isopropyl-6-methyl-3-oxoazepino[4,3-b]indol-
2(1H,3H,6H)-yl)-2-phenylacetamide (6h)
Compound 6h was synthesized following the general procedure using
5h (0.2 mmol, 89 mg); yield: 53 mg (60%); white solid; mp 138–
140 °C.
1H NMR (400 MHz, DMSO-d6): δ = 7.96 (d, J = 6.1 Hz, 1 H), 7.58 (br s, 1
H), 7.42–7.33 (m, 3 H), 7.28–7.21 (m, 2 H), 7.08–6.98 (m, 2 H), 6.79–
6.66 (m, 1 H), 6.58–6.50 (m, 1 H), 5.83 (s, 1 H), 3.64–3.61 (m, 1 H),
3.19 (d, J = 9.2 Hz, 1 H), 2.59 (s, 3 H), 1.71 (d, J = 6.8 Hz, 6 H), 1.25 (s, 9
H).
13C NMR (75 MHz, DMSO-d6): δ = 168.2, 166.5, 138.2, 137.5, 136.4,
135.1, 128.7, 128.3, 127.4, 125.3, 123.6, 122.4, 119.1, 118.3, 115.1,
109.6, 60.8, 50.5, 39.1, 32.1, 28.1, 25.2, 22.6.
HRMS: m/z calcd for C28H33N3O2: 443.2573; found: 443.2582.
N-tert-Butyl-2-(6-methyl-3-oxo-5-phenylazepino[4,3-b]indol-
2(1H,3H,6H)-yl)-2-phenylacetamide (6i)
Compound 6i was synthesized following the general procedure using
5i (0.2 mmol, 95 mg); yield: 78 mg (82%); light yellow solid; mp 180–
182 °C.
1H NMR (300 MHz, DMSO-d6): δ = 7.88 (br s, 1 H), 7.53–7.42 (m, 3 H),
7.40–7.06 (m, 10 H), 6.93–6.70 (m, 1 H), 6.54 (s, 1 H), 6.10 (s, 1 H),
4.78–4.14 (m, 2 H), 3.10 (s, 3 H), 1.25 (s, 9 H).
13C NMR (75 MHz, CDCl3): δ = 168.0, 139.5, 139.3, 138.8, 136.3, 134.4,
134.2, 129.4, 129.1, 128.1, 128.0, 125.7, 124.0, 123.2, 119.4, 117.2,
109.3, 109.2, 51.3, 38.8, 34.1, 32.3, 28.3.
HRMS: m/z calcd for C31H31N3O2: 477.2416; found: 477.2439.
N-tert-Butyl-2-(6-methyl-3-oxo-5-p-tolylazepino[4,3-b]indol-
2(1H,3H,6H)-yl)-2-phenylacetamide (6j)
Compound 6j was synthesized following the general procedure using
5j (0.2 mmol, 98 mg); yield: 91 mg (93%); white solid; mp 281–
283 °C.
1H NMR (300 MHz, DMSO-d6): δ = 7.87 (br s, 1 H), 7.35–7.06 (m, 11
H), 6.93–6.68 (m, 1 H), 6.51 (s, 1 H), 6.09 (s, 1 H), 4.81–3.97 (m, 2 H),
3.11 (s, 3 H), 2.36 (s, 3 H), 1.26 (s, 9 H).
13C NMR (75 MHz, DMSO-d6): δ = 168.5, 166.5, 138.5, 138.1, 136.2,
135.5, 129.4, 128.8, 128.5, 127.6, 127.5, 125.2, 122.7, 119.1, 116.7,
109.6, 60.6, 50.3, 32.0, 28.2, 20.7.
HRMS: m/z calcd for C32H33N3O2: 491.2573; found: 491.2562.© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2015, 47, 1337–1347
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Compound 6l was synthesized following the general procedure using
5l (0.2 mmol, 80 mg); yield: 25 mg (31%); off-white solid; mp 110–
112 °C.
1H NMR (300 MHz, CDCl3): δ = 7.51–7.36 (m, 5 H), 7.34–7.27 (m, 3 H),
7.05 (t, J = 7.74 Hz, 1 H), 6.50 (s, 1 H), 6.42 (s, 1 H), 5.91 (s, 1 H), 5.77
(br s, 1 H), 5.01 (d, J = 17.31 Hz, 1 H), 4.23 (d, J = 17.52 Hz, 1 H), 3.90 (s,
3 H), 1.38 (s, 9 H).
13C NMR (75 MHz, CDCl3): δ = 168.5, 164.5, 139.6, 134.8, 130.3, 129.3,
129.2, 128.9, 128.5, 123.7, 123.5, 119.7, 118.8, 115.4, 109.3, 108.7,
61.6, 51.8, 42.6, 32.0, 28.6.
HRMS: m/z calcd for C25H27N3O2: 401.2103; found: 401.2080.
(Z)-N-tert-Butyl-3,3-dimethyl-2-(4-oxo-6-phenyl-1H-azocino[5,4-
b]indol-3(2H,4H,7H)-yl)butanamide (9a); Typical Procedure
In a 10 mL screw cap vial charged with Ugi adduct 8a (0.2 mmol, 91
mg) was added AuPPh3Cl (5 mol%, 5 mg), AgSbF6 (5 mol%, 3.5 mg), and
CHCl3 (2 mL). The vial was sealed and subsequently heated at 50 °C for
3–5 h. After completion of the reaction (confirmed by TLC analysis,
eluent: 30% Et2O in CH2Cl2), the residue was subjected to silica gel col-
umn chromatography (using 10–30% Et2O–CH2Cl2) to afford indoloaz-
epinone 9a; yield: 73 mg (80%); white solid; mp 220–222 °C.
1H NMR (300 MHz, CDCl3): δ = 10.58 (s, 1 H), 7.85 (br s, 1 H), 7.49–
7.25 (m, 7 H), 7.20 (d, J = 8.10 Hz, 1 H), 7.07 (d, J = 7.53 Hz, 1 H), 6.96
(t, J = 7.53 Hz, 1 H), 6.43 (s, 1 H), 4.97–4.78 (m, 1 H), 4.41–4.17 (m, 2
H), 2.99–2.79 (m, 1 H), 1.23 (s, 9 H), 0.99 (s, 9 H).
13C NMR (75 MHz, CDCl3): δ = 172.2, 170.7, 168.5, 139.3, 135.8, 129.7,
129.0, 128.8, 128.6, 128.4, 123.2, 122.7, 119.5, 119.0, 112.1, 110.6,
51.3, 35.4, 31.8, 28.3, 26.4, 22.6, 14.1.
HRMS: m/z calcd for C29H35N3O2: 457.2729; found: 457.2706.
(Z)-N-Butyl-2-(2,6-dichlorophenyl)-2-(6-methyl-4-oxo-1H-azoci-
no[5,4-b]indol-3(2H,4H,7H)-yl)acetamide (9b)
Compound 9b was synthesized following the general procedure using
the readily synthesized Ugi adduct 8b (0.2 mmol, 97 mg) and the data
for this compound were found in accordance with the literature re-
port;10 yield: 78 mg (80%); white solid; mp 250–253 °C.
1H NMR (300 MHz, DMSO-d6): δ = 10.8 (s, 1 H), 7.95–7.66 (m, 1 H),
7.50–7.31 (m, 3 H), 7.25 (d, J = 8.22 Hz, 1 H), 7.07 (t, J = 7.22 Hz, 1 H),
6.88 (t, J = 7.45 Hz, 1 H), 6.80–6.69 (m, 1 H), 6.37 (s, 1 H), 5.97 (s, 1 H),
4.35–4.07 (m, 1 H), 3.96–3.82 (m, 1 H), 3.10–2.90 (m, 2 H), 2.76–2.54
(m, 1 H), 2.28 (s, 3 H), 2.04–1.88 (m, 1 H), 1.40–1.10 (m, 4 H), 0.88–
0.78 (m, 3 H).
13C NMR (75 MHz, DMSO-d6): δ = 168.7, 167.1, 135.7, 134.2, 132.0,
131.8, 130.6, 129.4, 128.0, 122.0, 121.9, 118.8, 117.8, 110.6, 107.7,
57.3, 44.2, 30.5, 24.8, 23.6, 19.5, 13.6.
HRMS: m/z calcd for C26H27Cl2N3O2: 483.1480; found: 483.1468.
(Z)-N-tert-Butyl-2-cyclohexyl-2-(10-methoxy-6-methyl-4-oxo-1H-
azocino[5,4-b]indol-3(2H,4H,7H)-yl)acetamide (9c)
Compound 9c was synthesized following the general procedure using
the readily synthesized Ugi adduct 8c (0.2 mmol, 90 mg) and the data
of this compound were found in accordance with the literature re-
port;10 yield: 59 mg (65%); white solid; mp 218–220 °C.
1H NMR (300 MHz, DMSO-d6): δ = 10.64 (s, 1 H), 7.53 (br s, 1 H), 7.16
(d, J = 8.69 Hz, 1 H), 6.79 (s, 1 H), 6.72 (dd, J = 1.70, 8.75 Hz, 1 H), 5.88
(s, 1 H), 4.62–4.49 (m, 1 H), 4.20–4.07 (m, 1 H), 3.99–3.85 (m, 1 H),
3.71 (s, 3 H), 3.14–2.80 (m, 2 H), 2.20 (s, 3 H), 2.02–1.88 (m, 1 H),
1.72–1.50 (m, 3 H), 1.49–1.17 (m, 3 H), 1.12 (s, 9 H), 1.08–0.79 (m, 3
H).
13C NMR (75 MHz, CDCl3): δ = 170.8, 169.4, 154.0, 134.5, 132.1, 131.0,
129.2, 121.4, 113.7, 111.4, 109.8, 100.2, 55.8, 51.0, 35.6, 30.2, 29.1,
28.3, 26.3, 25.7 (2), 23.9.
HRMS: m/z calcd for C27H37N3O3: 451.2835; found: 451.2847.
(Z)-N-Cyclohexyl-2-[6-(4-methoxyphenyl)-4-oxo-1H-azocino[5,4-
b]indol-3(2H,4H,7H)-yl]-2-phenylacetamide (9d)
Compound 9d was synthesized following the general procedure using
8d (0.2 mmol, 107 mg); yield: 97 mg (91%); white solid; mp 271–
273 °C.
1H NMR (300 MHz, DMSO-d6): δ = 10.59 (s, 1 H), 7.74 (d, J = 7.6 Hz, 1
H), 7.46–7.04 (m, 9 H), 7.01–6.91 (m, 4 H), 6.35 (s, 1 H), 5.87 (s, 1 H),
4.42–4.07 (m, 1 H), 3.93–3.64 (m, 4 H), 3.58–3.45 (m, 1 H), 2.49–2.31
(m, 1 H), 2.12–1.81 (m, 1 H), 1.69–1.43 (m, 5 H), 1.28–1.11 (m, 2 H),
1.08–0.70 (m, 3 H).
13C NMR (75 MHz, DMSO-d6): δ = 169.2, 159.7, 136.8, 136.0, 131.6,
130.4, 129.3, 129.1, 128.4, 127.8, 122.0, 121.1, 118.3, 118.1, 113.8,
111.0, 110.5, 55.2, 54.8, 47.6, 32.0, 25.0, 24.5, 24.4.
HRMS: m/z calcd for C34H35N3O3: 533.2678; found: 533.2677.
(Z)-N-tert-Butyl-2-(10-methoxy-4-oxo-6-phenyl-1H-azocino[5,4-
b]indol-3(2H,4H,7H)-yl)pentanamide (9e)
Compound 9e was synthesized following the general procedure using
8e (0.2 mmol, 95 mg); yield: 80 mg (84%); off-white solid; mp 258–
260 °C.
1H NMR (300 MHz, THF-d8): δ = 9.46 (s, 1 H), 7.47 (br s, 1 H), 7.33–
7.12 (m, 5 H), 6.92 (d, J = 8.64 Hz, 1 H), 6.84 (s, 1 H), 6.61 (d, J = 8.28
Hz, 1 H), 6.51 (br s, 1 H), 6.18 (s, 1 H), 4.59–4.41 (m, 1 H), 4.07–3.91
(m, 1 H), 3.67 (s, 3 H), 3.28–2.90 (m, 2 H), 1.98–1.76 (m, 1 H), 1.59–
1.46 (m, 1 H), 1.25–1.02 (m, 2 H), 0.94 (s, 9 H), 0.77 (t, J = 7.05 Hz, 3
H).
13C NMR (75 MHz, THF-d8): δ = 167.4 (2), 152.2, 138.7, 136.1, 129.9,
128.8, 127.1, 126.4, 126.2 (2), 121.1, 111.3, 109.4, 97.6, 52.9, 48.2,
29.1, 25.8, 24.0, 17.6, 11.6.
HRMS: m/z calcd for C29H35N3O3: 473.2673; found: 473.2663.
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